Medical Management of Renal Cell Cancer by Turner, Jennifer et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
Provisional chapter
Medical Management of Renal Cell Cancer
Jennifer Turner, Adrian Simoes, Albert Edwards and
Rakesh Raman
Additional information is available at the end of the chapter
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Je ifer T r er, ria  Si es, l ert E ar s 
and Rakesh Raman
dditional infor ation is available at the end of the chapter
Abstract
In 2018, there were an estimated 400,000 new cases of renal cell carcinoma (RCC) world-
wide—with 64,000 cases in the United States and 12,600 in the United Kingdom (UK). 
The medical management of RCC is an integral part of treatment as between one-quarter 
and one-third of patients will present with metastatic disease. There has been a rapid 
evolution of targeted and novel treatments for RCC over the last two decades. This chap-
ter explores the biology of renal cell carcinoma and current treatment strategies.
Keywords: renal cell carcinoma, metastatic renal cell carcinoma,  
tyrosine kinase inhibitor, targeted treatment, risk stratification
1. Introduction
Renal cell carcinoma (RCC) is the fourteenth most common cancer internationally [1]. There were 
estimated to be around 400,000 new cases worldwide in 2018, with 64,000 cases in the United 
States of America and 12,600 in the United Kingdom (UK) [1–3]. The increasing incidence of 
RCC worldwide over the past three decades has been attributed to increasing obesity, increasing 
height, and increasing tobacco smoking [4, 5]. RCC is also noted to be twice as prevalent in men 
than women [4]. Overall, 25–30% of patients have locally advanced RCC or metastatic disease at 
presentation [6], although in the UK, the proportion is 40% [3]. Systemic therapy and, in selected 
cases, surgical intervention has an important role in the management of metastatic RCC. The 
landscape of available systemic treatment options has developed rapidly over the past 10 years 
with a wide variety of systemic strategies now being employed. This chapter will review current 
therapies in the metastatic setting, consider the evidence for adjuvant systemic treatment, as well 
as look at some of the promising new therapies that are likely to emerge in the coming years.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Histological subtypes
Renal cell carcinoma is divided into several histological subtypes, of which the most common 
is clear cell renal cell carcinoma (ccRCC), accounting for approximately three-quarters of all 
kidney cancers [7]. Clear cell RCC originates from the epithelium of the proximal convo-
luted tubules. Most are sporadic, but there is a strong familial connection with those with a 
first-degree relative more likely to be effected and around 5% are associated with hereditary 
conditions such as Von Hippel–Lindau disease, tuberous sclerosis, and adult polycystic dis-
ease. The next most prevalent histological subtypes are papillary (10%) and chromophobe 
(5%) [7]. These three histological subtypes make up 90% of renal cell carcinomas and are also 
most common in patients over the age of 50 years. Other rarer subtypes, such as medullary 
and Xp11 translocation, are typically seen in younger people. A better understanding of the 
genetic drivers for renal cell carcinoma has led to the development of targeted systemic agents 
and revolutionised the metastatic treatment landscape.
3. Staging and risk stratification in renal cell carcinoma
Staging for RCC is based on the TNM 8 classification and staging groups [8]. The staging takes 
into account the size and loco-regional extent of the tumour in addition to lymph node and 
distant metastatic spread [9]. Table 1 illustrates this is in further detail.
In metastatic renal cell carcinoma, the decision to treat and, more importantly the choice of 
initial treatment, is based on risk stratification of the patients into three groups. The choice 
of initial systemic therapy in metastatic RCC may be informed by risk stratification using 
the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic 
model [10–12].
The six adverse risk factors in the IMDC model are as follows [11]:
• time from original diagnosis to initiation of targeted therapy <1 year;
• Karnofsky performance score < 80;
• haemoglobin < lower limit of normal;
• neutrophil > upper limit of normal;
• platelet > upper limit of normal; and
• serum calcium > upper limit of normal.
Patients with none of these risk factors are considered to be in the favourable-risk group, 
those with one or two are considered to be in the intermediate-risk group, and those with 
three or more risk factors are considered to be in the poor-risk group. These groups correlate 
with median overall survival: 43.2 months in the favourable-risk group, 22.5 months in the 
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intermediate-risk group, and 7.8 months in the poor-risk group [11]. Oncologists use this, or 
similar risk stratification, to decide upon the most appropriate treatment from the systemic 
options available. The advantage of the IMDC-model-based risk stratification is that it has 
been validated in both clear cell and non-clear cell histopathological groups and after first line 
and subsequent lines of treatment [11–14].
TX
T0
T1
T1a
T1b
T2
T2a
T2b
T3
T3a
T3b
T3c
T4
Primary tumour cannot be assessed
No evidence of primary tumour
Tumour ≤7 cm in greatest dimension, limited to the kidneys
Tumour ≤4 cm in greatest dimension, limited to the kidneys
Tumour >4 and ≤7 cm in greatest dimension, limited to the kidneys
Tumour >7 cm in greatest dimension, limited to the kidneys
Tumour >7 and ≤10 cm in greatest dimension, limited to the kidneys
Tumour >10 cm in greatest dimension, limited to the kidneys
Tumour extends into major veins or perinephric tissues, but not into the ipsilateral 
adrenal gland and not beyond Gerota’s fascia
Tumour extends into the renal veins or its segmental branches, or invades the 
pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota’s 
fascia
Tumour extends into the vena cava below the diaphragm
Tumour extends into the vena cava above the diaphragm or invades the wall of the vena 
cava
Tumour invades beyond Gerota’s fascia (including contiguous extension into the 
ipsilateral adrenal gland)
NX
N0
N1
Regional lymph nodes cannot be assessed
No regional lymph nodes metastasis
Metastasis in regional lymph node(s)
M0
M1
No distant metastasis
Distant metastasis
Prognostic groups
T stage N stage M stage Stage group
T1 N0 M0 I
T1 N1 M0 III
T2 N0 M0 II
T2 N1 M0 III
T3 Nx, N0 M0 III
T3 N1 M0 III
T4 Any N M0 IV
Any T Any N M1 IV
Table 1. TNM staging of renal cell carcinoma [8].
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4. Metastatic systemic treatment options
4.1. Overview
The treatment objective in metastatic cancer is different to the primary setting. Treatment is 
palliative and the benefits, in terms of progression-free and overall survival, must be carefully 
balanced against the quality of life of the patient and potential side effects that any treatment 
may cause. The evolution of therapies has led to an increase in the median overall survival 
in metastatic RCC to beyond 2 years, and is likely to increase further as more treatments are 
developed [15–17].
4.2. Tyrosine kinase inhibitors
Tyrosine kinase inhibitors (TKIs) are a mainstay of targeted treatment in renal cell carcinoma. 
The drugs are designed to inhibit tyrosine kinases and enzymes, which themselves activate 
pathways of growth within the tumour cell. There are many different targets for TKIs, and 
in renal cell carcinoma, agents are targeted at vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), and the mammalian target of rapamycin (mTOR). 
Over half of patients have abnormalities in the von Hippel Lindau (VHL) gene, which leads 
to an increased expression of hypoxia inducible factors (HIF) [18]. In turn, accumulation of 
HIF switches on hypoxia-inducible genes such as VEGF and PDGF, and further downstream, 
mTOR. Expression of VEGF and mTOR drives tumour growth and angiogenesis [18].
The most commonly used TKIs employing VEGF are sorafenib, sunitinib, pazopanib, axitinib, 
and cabozantinib, and employing mTOR everolimus and temsirolimus. The action of these 
agents at a cellular level is illustrated in Image 1. Multiple clinical trials have shown the effi-
cacy of these agents in RCC and are summarised in Table 2. The most commonly observed 
side effects for TKI therapy are rash, diarrhoea, hypertension, fatigue, and palmar-plantar 
erythrodysesthesia syndrome (hand-foot syndrome) [19–26].
Bevacizumab has also been used in renal cell cancer. Bevacizumab is a monoclonal antibody, 
which blockades the VEGF ligand, binding with VEGF-A. Initial trials of bevacizumab versus 
interferon alpha (IFN-𝛂) showed a progression-free survival (PFS) benefit, but no OS benefit 
as crossover was allowed on progression [27]. When used in combination, IFN-𝛂 bevacizumab 
showed a higher response rate and PFS, but again OS was not demonstrated, and there was 
also significant toxicity [27]. Although it remains a first-line treatment option, in practice, 
due to the high toxicity of the treatment and efficacy of other first-line treatment options, it is 
rarely used. Trials also explored the combination of bevacizumab and mTOR inhibitors; how-
ever, no clinical benefit was determined and toxicity proved to be a limiting factor [28–31].
4.3. Immunotherapy
One of the most exciting areas of development in systemic therapy has been immunotherapy. 
The purpose of immunotherapy is to unmask the cancer to the body’s own immune system. 
Historically, IFN-𝛂 has been used in RCC with a modest effect, and overall response rates 
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(ORR) were around 10–15% [17]. More recently, studies have investigated Nivolumab, a 
fully human IgG4 anti-programmed cell death-1 antibody (anti-PD-1) that selectively blocks 
the interaction between PD-1 and its ligands PD-L1 and PD-L2 and RCC [17, 32]. In the 
CheckMate 025 study, patients were randomised to receive either nivolumab or everolimus, 
OS was 25 vs. 19 months in favour of nivolumab, and less grade 3 or 4 toxicity was seen in the 
nivolumab arm [33]. This trial led to the FDA approval of nivolumab for RCC in 2015 with 
European approval quickly following.
After the success of single agent immunotherapy, attention turned to the investigation of 
combination immunotherapy in metastatic RCC. Here, nivolumab was used in combination 
with a second agent ipilimumab, a monoclonal antibody, which targets cytotoxic T lympho-
cyte-associated antigen 4 (CTLA-4). CheckMate 214 trial randomised nivolumab and ipilim-
umab against sunitinib. Median OS was not reached in the combination immunotherapy arm 
compared to the immunotherapy used for 26 months with sunitinib, and PFS was 11.6 vs. 
8.4 months in favour of combination immunotherapy [16].
The mechanism of action of the various immunotherapy agents can be complex. In short, they 
upregulate the body’s own immune response against the ‘foreign’ tumour cells. For those 
Image 1. A graphic showing how loss of the von Hippel Lindau (VHL) protein results in up regulation of hypoxia 
induced factors (HIF) and in turn vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) 
and the actions of targeted therapies.
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Trial Drug Number of 
patients (n)
Line of 
treatment
Disease-free 
survival (DFS) 
(months)
Overall survival 
(OS) (months)
Motzer et al.: 
sunitinib versus 
interferon alpha in 
metastatic renal cell 
carcinoma [19]
Sunitinib versus 
interferon alpha
750 First line Sunitinib 11
interferon alpha 5
HR 0.42 p < 0.001
Sunitinib 28.7
Interferon alpha 
23.7
HR 0.8209 p = 0.051
Sternberg et al.: 
pazopanib 
in locally advanced 
or metastatic renal 
cell carcinoma: 
results of a 
randomised phase 
III trial [20]
Pazopanib versus 
placebo
435 Treatment 
naive or 
cytokine 
pretreated
Pazopanib 9.2
placebo 4.2
HR 0.46 P < 0.001
Not available
Motzer et al.: 
pazopanib versus 
sunitinib in 
metastatic renal cell 
carcinoma [21]
Sunitinib versus 
pazopanib
1110 First line Sunitinib 9.5
Pazopanib 8.8
HR 1.05
Sunitinib 29.3
Pazopanib 28.4
Hudes et al.: 
temsirolimus, 
interferon alpha,  
or both for 
advanced renal cell 
carcinoma [22]
Interferon 
alpha versus 
temsirolimus 
versus 
temsirolimus plus 
interferon alpha
626
(poor 
prognosis)
First line Interferon alpha 
3.1
temsirolimus 5.5
temsirolimus plus 
interferon alpha 
4.7
Interferon alpha 7.3
temsirolimus 10.9
temsirolimus plus 
interferon alpha 8.4
Escudier et al.: 
sorafenib in 
advanced clear  
cell renal cell 
carcinoma [23]
Sorafenib versus 
placebo
903 First line Sorafenib 5.5
placebo 2.8
HR 0.44 P < 0.01
Sorafenib not 
reached
placebo not reached
HR 0.72 P < 0.001
Rini et al.: 
comparative 
effectiveness of 
axitinib versus 
sorafenib in 
advanced renal cell 
carcinoma (AXIS): a 
randomised phase 
3 trial [24]
Axitinib versus 
sorafenib
723 Second line Axitinib 6.7
Sorafenib 4.7
Not available
Choueiri et al.: 
cabozantinib 
versus everolimus 
in advanced renal 
cell carcinoma 
(METEOR): final 
results from a 
randomised, 
open-label, phase 3 
trial [25]
Cabozantinib 
versus everolimus
658 Second line or 
subsequent
Cabozantinib 7.4 
everolimus 3.9
HR 0.051 
p < 0.0001
Cabozantinib 18.8 
everolimus 16.5
HR 0.66 p = 0.00026
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who wish for a fuller explanation, the cellular mechanism of the immunotherapy agents is 
now outlined. In the tumour microenvironment, tumour neoantigens are released by can-
cer cells. These are captured by antigen presenting cells (APCs). These neoantigens cause 
the expression of major histocompatibility complexes (MHC) and T-cell receptors (TCRs) on 
the surface of CD8+ cytotoxic T cells. PD-1 expression is induced. Tumour cells can highly 
express PD-L1 and PD-L2, which can bind with PD-1 on the T cell and ultimately lead to T-cell 
exhaustion. Drugs such as nivolumab and pembrolizumab inhibit the interaction of PD-1 
with PD-L1 and PD-L2, which results in enhanced T-cell cytotoxicity, increased cytokine, 
and tumour-associated macrophage activity. Anti-PD-L1 antibody therapies such as atezoli-
zumab, durvalumab and avelumab, specifically target the interaction between PD-L1 and 
PD-1. Tumour neoantigens also cause peptides bound to MHC II molecules to be presented to 
CD4+ T helper cells. Through a series of co-stimulatory signals transmitted via CD28 T cells, 
CTLA-4 is upregulated. The upregulated CTLA-4 competes with CD28 to bind with CD80 
and/or CD86 on the APC. The interaction of CTLA-4 with CD80 or CD86 results in inhibitory 
signalling, which in turn promotes tumour growth. Ipilimumab is an anti-CTLA-4 antibody; 
thus, it blocks CTLA-4, allowing an enhanced immune response [34]. A pictorial explanation 
of the mechanism of both CTLA-4 and PD-1 immunotherapy targeted agents is available in 
Image 2.
Immunotherapy has a different safety profile from targeted TKI therapies or standard chemo-
therapies. Typically, autoimmune reactions are seen that can be varying and at times severe. 
The most common is diarrhoea and colitis, but pneumonitis and endocrine problems are also 
observed.
There has also been some investigation in using the combinations of immunotherapy with 
targeted agents. Nivolumab was paired with pazopanib or sunitinib in the CheckMate 014 
trial; however, toxicity was very high with 70% of patients experiencing a grade 3 or 4 toxicity 
and 25% discontinuing the treatment due to toxicity. This trial has led to caution in combining 
immunotherapy and TKIs [35] (Table 3).
Trial Drug Number of 
patients (n)
Line of 
treatment
Disease-free 
survival (DFS) 
(months)
Overall survival 
(OS) (months)
Armstrong et al.: 
everolimus 
versus sunitinib 
for patients 
with metastatic 
non-clear cell renal 
cell carcinoma 
(ASPEN): a 
multicentre, open-
label, randomised 
phase 2 trial [26]
Everolimus versus 
sunitinib
108
(non-clear cell 
histology)
First line Everolimus 5.6
Sunitinib 8.3
HR 1.41 p = 0.16
Everolimus 13.2
Sunitinib 31.5
HR1.12 p = 0.60
Table 2. Trials of tyrosine kinase inhibitors in the metastatic renal cancer setting.
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4.4. Sequencing of agents
The natural history of targeted agents in all cancers, and reflected here in RCC, is develop-
ing ultimate resistance. Therefore, a patient may undertake several lines of treatment. Both 
the European Society of Medical Oncology (ESMO) and National Comprehensive Cancer 
Trial Drug Number of 
patients (n)
Line of 
treatment
Progression-free survival 
(PFS) (months)
Overall survival 
(OS) (months)
CheckMate 025
Motzer et al. [33]
Nivolumab versus 
everolimus
823 Second or 
subsequent
Nivolumab 4.6 
Everolimus 4.4
HR 0.88 p = 0.11
Nivolumab 25.0 
Everolimus 19.6
HR 0.73 p = 0.002
CheckMate 214
Motzer et al. [16]
Nivolumab plus 
ipilimumab 
(nivo+ipi) versus 
sunitinib
1096 First line Nivo+ipi 11.6
Sunitinib 8.4
Nivo+ipi-not reached
Sunitinib 26.0
18 months of OS rate
Nivo+ipi 75%
sunitinib 60%
CheckMate 016
Amin et al. [35]
Nivolumab in 
combination 
with sunitinib or 
pazopanib
55 First line Nivolumab plus sunitinib 
12.7
Nivolumab plus 
pazopanib 7.2
Nivolumab plus 
sunitinib not reached
Nivolumab plus 
pazopanib 27.9
Table 3. Immunotherapy trials in metastatic renal cell carcinoma.
Image 2. Pictorial representation of the mechanism of action of immunotherapy agents.
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Network (NCCN) provide up-to-date guidelines advising oncologists of the latest evidence 
to help determine the most advantageous sequence of agents [36, 37]. At the time of publica-
tion, we would suggest a suitable sequence of therapies to be followed: first-line sunitinib 
or pazopanib (in poor-risk patients temsirolimus), second-line axitinib or nivolumab, with 
a preference to nivolumab in poor-risk patients, and third-line cabozantinib [36]. In non-cell 
histology, sunitinib is recommended first line, although few trials have specifically recruited 
non-clear cell histological subtypes for investigation [26, 36].
We recognise that as new agents are developed and further research is conducted in this field, 
the advice may change. Another strategy that has been investigated is active surveillance. 
Patients with indolent metastatic disease may safely remain on surveillance until their disease 
begins to progress. A cohort study of patients with metastatic RCC on surveillance demon-
strated a median time to starting systemic therapy of 14.9 months [38].
5. Cytoreductive nephrectomy in the age of TKI
Historically, cytoreductive nephrectomy has been used in metastatic disease in a selected 
number of patients. It has been especially used in fit patients with asymptomatic, low bur-
den of metastatic disease and troublesome local symptoms such as bleeding and pain [39]. 
However, publication of the CARMENA trial in 2018, where sunitinib versus cytoreduc-
tive nephrectomy plus sunitinib was evaluated, demonstrated non-inferiority of sunitinib 
alone [40]. The trial was designed to demonstrate non-inferiority and non-superiority of 
one investigational arm; however, it was noted that the median OS of sunitinib alone was 
18.4 months versus 13.9 months as compared to sunitinib with nephrectomy [40]. Although 
further evaluation is required, and for symptomatic management, cytoreductive nephrec-
tomy may still be beneficial in the metastatic setting, this new evidence has called into ques-
tion the validity of this approach routinely used for patients in the contemporary systemic 
treatment setting.
6. Oligometastatic disease in kidney cancer
An interesting development across oncology in all tumour groups has been the change in 
approach to the management of oligometastatic disease [41]. Oligometastatic disease is a term 
used to describe a patient with a small number of metastatic lesions; in most studies, this is 
defined as 1–3 or 1–5 lesions [41]. Aggressive resection of the metastasis can be attempted 
surgically or an increasing number of patients can be treated with high doses of radiotherapy 
using stereotactic ablative body radiotherapy (SABR) [41, 42]. Traditionally, RCC has been 
thought to be a radio-resistant disease; however, large ablative doses of radiotherapy used 
in an SABR technique induce different pathways of apoptosis and as such good long-term 
control can be achieved in certain patients. Metastasis in bone, lungs, brain, lymph nodes, and 
adrenal glands are all potentially treatable with SABR [43–45].
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Metastasectomy can be employed for metastatic disease in a number of sites including bone, 
lungs and brain. Good long-term outcomes have been observed, especially with careful 
patient selection [46, 47].
A combination of metastasectomy and post-operative SABR for brain metastasis has been 
employed with excellent results and has been shown to have less side effects than post-oper-
ative treatment with whole brain radiotherapy [48].
7. Adjuvant treatment
Adjuvant therapy in oncology describes the use of additional treatment alongside the pri-
mary, definitive, usually surgical, treatment, in an attempt to achieve higher rates of progres-
sion-free and overall survival. In RCC, this has not been widely employed as many trials have 
shown adjuvant treatment in early stage renal cancer not to translate into an overall survival 
benefit [49, 50]. However, it is also recognised that many patients with early stage disease 
will also go on to relapse, and therefore, interest in this area has remained high and guide-
lines recommend that for intermediate- and high-risk patients, adjuvant treatment, as part 
of a clinical trial, should be considered [36, 49]. In ASSURE trial, sunitinib or sorafenib failed 
to demonstrate an improvement in disease-free survival (DFS) compared to placebo [51]. In 
S-TRAC trial, sunitinib did increase 5-year DFS, but not overall survival data, although the 
overall survival data have not yet improved [52]. In the PROTECT trial, pazopanib failed to 
Trial Drug Number of 
patients (n)
Disease-free 
survival (DFS)
Overall survival (OS)
ASSURE
Haas et al. [50]
Sorafenib/Sunitinib versus 
placebo
1943 Sorafenib 6.1 years
(HR 0.97 P = 0.718)
Sunitinib 5.8 years
(HR 1.02 P = 0.804)
Placebo 6.6 years
At 5 years
Sorafenib 80.5%
Sunitinib 77.9%
Placebo 80.3%
No significant difference 
between groups
S-TRAC
Ravaud et al. [51]
Sunitinib versus placebo 615 Sunitinib 6.8 years
Placebo 5.6 years
(HR 0.76 P = 0.03)
Mature data not 
available.
PROTECT
Motzer et al. [52]
Pazopanib versus placebo 1538 HR 0.86
P = 0.165
Not available
ATLAS
Gross-Goupil et al. 
[53]
Axitinib versus placebo 724 HR 0.870
P = 0.3211
Not available
Table 4. Trials of tyrosine kinase inhibitors in the adjuvant renal cancer setting post-nephrectomy.
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show a statistically significant improvement in DFS [53]. In the ATLAS trial, using axitinib in 
the adjuvant setting, the primary end point was not reached and the study was abandoned 
due to futility at the interim assessment point [54]. It is also worth noting that the majority 
of patients in these adjuvant trials had ccRCC histology. A summary of the reported trials is 
shown in Table 4.
Several trials are still ongoing using targeted therapies in high-risk patients post-nephrectomy 
including: SORCE trial (NCT00492258) assessing sorafenib and EVEREST trial (NCT01120249) 
investigating everolimus [50]. Further trials are underway to assess the use of immunotherapy 
in the adjuvant setting using a variety of checkpoint inhibitors. These include the IMmotion101 
trial (NCT03024996) with atezolizumab, PROSPER trial (NCT03055013) comparing neoadju-
vant and adjuvant nivolumab versus observation, KEYNOTE-564 trial (NCT03142334) evalu-
ating pembrolizumab versus placebo and CheckMate 914 trial (NCT03138512) comparing 
nivolumab with ipilimumab versus placebo [50]. The results of these trials are likely to be 
reported in the coming years; however, the standard of care at present is not to prescribe 
adjuvant therapy, of any kind, post-nephrectomy in renal cell carcinoma.
8. Emerging treatments and trends
An area of particular interest for oncologist is the search for reliable biomarkers, which will 
guide us into targeting our treatments to the patients who will benefit from them the most. 
Renal cell carcinoma is no exception and the hunt for a biomarker is of high interest to aca-
demics and drug companies alike. Biomarkers are being investigated in the areas of imag-
ing serum, histology, and urine, both to determine treatment strategies and to differentiate 
between benign and malignant processes [55]. One biomarker of particular interest is carbonic 
anhydrase IX, which has demonstrated excellent specificity and ability to predict treatment 
response [56]. Researchers are also keen to identify reliable biomarkers for use with immune 
checkpoint inhibitors in the treatment of RCC, especially to help differentiate between the 
progression and pseudoprogression on treatment [57].
Research has been conducted on the use of vaccine therapy in RCC. Vaccines are designed 
to induce a specific immune response in the patient; however, this is yet to translate into 
an overall survival benefit [58, 59]. In the new era of targeted medicine and next-generation 
immunotherapy, the role of vaccines remains uncertain and only further research in this area, 
with associated success in randomised trials, will confirm vaccine therapy as a viable treat-
ment strategy for the future.
Interesting evidence has been published on the use of SABR in patients who are not fit for 
partial nephrectomy. High doses of highly targeted radiotherapy are given to the tumour 
patients with the hope of ablation of the tumour. The treatment was well tolerated with 
low toxicity and good local control rates in 2 years [60]. Further ongoing evaluation of 
this technique is needed, but it is likely that use of SABR in this format will increase in 
the future.
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9. Summary
The take-home points are as follows:
• prognostic risk stratification is used to guide treatment decisions in metastatic renal cell 
carcinoma patients;
• the mainstay of treatment for metastatic renal cell carcinoma is TKI therapy;
• immunotherapy has been shown to be effective in metastatic renal cell carcinoma and is 
now routinely used;
• cytoreductive nephrectomy should not be used routinely in metastatic renal cell carcinoma 
patients;
• adjuvant systemic treatment lacks robust evidence for routine use in renal cell carcinoma 
patients outside of the clinical trial setting.
The medical treatment of renal cell carcinoma is rapidly evolving with the introduction of 
new treatments entering the market on a regular basis. Whilst this is challenging for the phy-
sician treating renal cell carcinoma, it is excellent news for our patients who will benefit from 
the greater arsenal of treatments available.
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